Results 21 to 30 of about 28,422 (269)

Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis

Journal of International Medical Research, 2022
Omalizumab is used for the treatment of persistent severe allergic asthma in adults and children. However, some patients remain symptomatic even after omalizumab treatment. In bronchial asthma, chronic inflammation of the bronchial wall causes thickening
Mitsuru Tsuge, Masanori Ikeda, Yoichi Kondo, Hirokazu Tsukahara   +3 more
doaj   +1 more source

Asthma referrals : a key component of asthma management that needs to be addressed [PDF]

, 2017
Peer reviewedPublisher ...
Bergen, David A, Bjermer, Leif, Martinez, Rafael, Price, David   +3 more
core   +1 more source

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

Frontiers in Immunology, 2022
Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events.
Peng Cao, Wenjing Xu, Litao Zhang
semanticscholar   +1 more source

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

World Allergy Organization Journal, 2019
Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up.
Ivan Cherrez-Ojeda, Marcus Maurer, Jonathan A. Bernstein, Emanuel Vanegas, Miguel Felix, German D. Ramon, Luis Felipe Ensina, José Ignacio Larco Sousa, Edgar Emilio Matos Benavides, R. Cardona Villa, P. Latour Staffeld, Blanca María Morfin-Maciel, Jose Mori, Paul Wilches C, Valeria L. Mata, Annia Cherrez   +15 more
doaj   +1 more source

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to
I. Agache, Jessica Beltran, C. Akdis, M. Akdiş, C. Canelo-Aybar, W. Canonica, T. Casale, T. Chivato, J. Corren, S. D. Del Giacco, T. Eiwegger, D. Firinu, J. Gern, E. Hamelmann, N. Hanania, M. Mäkelä, I. H. Martín, Parameswaran Nair, L. O’Mahony, N. Papadopoulos, A. Papi, Hae‐Sim Park, L. A. Pérez de Llano, M. Posso, Claudio Rocha, S. Quirce, J. Sastre, M. Shamji, Yang Song, Corinna Steiner, J. Schwarze, P. Alonso-Coello, Ó. Palomares, M. Jutel   +33 more
semanticscholar   +1 more source

Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab

The World Allergy Organization Journal, 2023
Vernal keratoconjunctivitis (VKC) is a severe ocular allergic disease characterized by chronic inflammation of the cornea and conjunctiva that may lead to loss of visual acuity and blindness. The disease occurs primarily in children and is more common in
S. Doan, N. Papadopoulos, Jason K. Lee, S. Leonardi, S. Manti, S. Lau, C. Rondón, Vibha Sharma, Uwe Pleyer, X. Jaumont, S. Lazarewicz   +10 more
semanticscholar   +1 more source

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients

Pulmonology, 2021
Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a ...
A. Arrobas, M.P. Barbosa, S. Rabiais, B. Vandewalle, J. Félix   +4 more
doaj   +3 more sources

Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]

, 2019
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus, Ren, Lei, Zhang, Luo, Zhang, Nan   +3 more
core   +1 more source

Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?

International Journal of Molecular Sciences, 2023
The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear.
R. Asero, S. Ferrucci, P. Calzari, D. Consonni, M. Cugno   +4 more
semanticscholar   +1 more source

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

Allergy & Rhinology, 2018
Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Abhishek Kavati, Dominic Pilon, Benjamin Ortiz, Brandee Paknis, Ashok Vegesna, Bradd Schiffman, Maryia Zhdanava, Patrick Lefebvre, Brian Stone   +8 more
doaj   +1 more source